Advanced Clinical Selects TRI RBM Platform
TRI will be providing the OPRA platform for all of Advanced’s studies whose sponsors have requested a risk-based approach to monitoring.
Advanced Clinical, a Chicago-based CRO, has selected Triumph Research Intelligence (TRI) OPRA RBM technology platform and accompanying RBM service offerings. TRI will be providing the OPRA platform for all of Advanced’s studies whose sponsors have requested a risk-based approach to monitoring. TRI will be supporting Advanced in optimizing their monitoring processes, implementing change management, and supporting study specific key risk indicator design.
Read the full
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
